Supplementary Figure S2: Combined MET and EGFR inhibition is more effective than monotherapy in TNBC 124 tumorgrafts. (A)
Growth of TNBC 124 PDX tumors were significantly inhibited by monotherapy of MGCD265 (40 mg/kg; p < 0.001), erlotinib (50 mg/kg; p < 0.01), and combination therapy of MGCD265 + erlotinib (p < 0.00001). Plot displays LOESS interpolated mean tumor volume and SE. (B) Pairwise comparisons reveal that combined MET and EGFR inhibition is more effective than monotherapy. Plot shows 95% confidence intervals for each pairwise difference between the growth rates of the three treatments (tumor volumes were log transformed). If the interval is to the left of the vertical line, then the treatment on the right-hand side of the "v" had a significantly slower growth rate. (C) Individual growth curves of treatment compared to vehicle demonstrate the variability in response to erlotinib (SD = 225 mm 3 ), MGCD265 (SD = 171 mm 3 ), or MGCD265 + erlotinib (SD = 86 mm 3 ). Linear mixed-effects modeling was used test for significant differences in tumor growth. All multiple comparisons were adjusted for multiple testing using a false discovery rate correction. 
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